Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (apre una nuova finestra)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indicizzato‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (apre una nuova finestra)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (apre una nuova finestra)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Fonte‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indicizzato‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (apre una nuova finestra)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (apre una nuova finestra)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indicizzato‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (apre una nuova finestra)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (apre una nuova finestra)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Fonte‎: Blood 2003;102(4):1529-30.

Indicizzato‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (apre una nuova finestra)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (apre una nuova finestra)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fonte‎: Transfusion 2007;47(10):1830-6.

Indicizzato‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (apre una nuova finestra)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (apre una nuova finestra)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Fonte‎: Iran J Blood Cancer 2009;1(4):147-50.

Indicizzato‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (apre una nuova finestra)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (apre una nuova finestra)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fonte‎: Int J Hematol 2012;95(1):51-6.

Indicizzato‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (apre una nuova finestra)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (apre una nuova finestra)

Perrine SP.

Fonte‎: Pediatr Ann 2008;37(5):339-46.

Indicizzato‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (apre una nuova finestra)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (apre una nuova finestra)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Fonte‎: Sci Rep. 2022;12(1):2752.

Indicizzato‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (apre una nuova finestra)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (apre una nuova finestra)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fonte‎: Haematologica 2004;89(10):1172-8.

Indicizzato‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (apre una nuova finestra)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (apre una nuova finestra)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fonte‎: Arch Iran Med 2009;12(3):295-7.

Indicizzato‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (apre una nuova finestra)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (apre una nuova finestra)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Fonte‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indicizzato‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (apre una nuova finestra)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (apre una nuova finestra)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Fonte‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indicizzato‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (apre una nuova finestra)

Fetal globin gene inducers: novel agents and new potential. (apre una nuova finestra)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Fonte‎: Ann N Y Acad Sci 2010;1202:158-64.

Indicizzato‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (apre una nuova finestra)